Skip to main content
PMC home page
Virologica Sinica logoLink to Virologica Sinica
. 2013 May 25;28(3):167–173. doi: 10.1007/s12250-013-3291-z

Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity

Malihe Naderi 1, Atefeh Saeedi 2, Abdolvahab Moradi 3, Mishar Kleshadi 3, Mohammad Reza Zolfaghari 1, Ali Gorji 4,5,6, Amir Ghaemi 3,4,✉
PMCID: PMC8208352  PMID: 23709057

Abstract

Hepatitis C virus (HCV) chronic infection is a worldwide health problem, and numerous efforts have been invested to develop novel vaccines. An efficient vaccine requires broad immune response induction against viral proteins. To achieve this goal, we constructed a DNA vaccine expressing nonstructural 3 (NS3) gene (pcDNA3.1-HCV-NS3) and assessed the immune response in C57BL/6 mice. In this study, the NS3 gene was amplified with a nested-reverse transcriptase-polymerase chain reaction (RT-PCR) method using sera of HCV-infected patients with genotype 1a. The resulting NS3 gene was subcloned into a pcDNA3.1 eukaryotic expression vector, and gene expression was detected by western blot. The resultant DNA vaccine was co-administered with interleukin-12 (IL-12) as an adjuvant to female C57BL/6 mice. After the final immunizations, lymphocyte proliferation, cytotoxicity, and cytokine levels were assessed to measure immune responses. Our data suggest that co-administration of HCV NS3 DNA vaccine with IL-12 induces production of significant levels of both IL-4 and interferon (IFN)-γ (p<0.05). Cytotoxicity and lymphocyte proliferation responses of vaccinated mice were significantly increased compared to control (p<0.05). Collectively, our results demonstrated that co-administration of HCV NS3 and IL-12 displayed strong immunogenicity in a murine model.

Keywords: Hepatitis C virus (HCV), NS3, Interleukin-12, DNA vaccine

References

  1. Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M. In vivoclearance of hepatitis C virus nonstructural 3/4A-expressing hepatocyte by DNA vaccine-primed cytotoxic T lymphocyte. J Infec Dis. 2005;192(12):2112–2116. doi: 10.1086/498218. [DOI] [PubMed] [Google Scholar]
  2. Ahlen G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I, Sällberg M. In vivoelectroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol. 2007;179(7):4741–4753. doi: 10.4049/jimmunol.179.7.4741. [DOI] [PubMed] [Google Scholar]
  3. Andre S, Seed B, Eberle J, Schraut W, Bültmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol. 1998;72(2):1497–1503. doi: 10.1128/jvi.72.2.1497-1503.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Arribillaga L, de Cerio A L, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borrás-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, Lasarte J J. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV recombinant vaccinia virus. Vaccine. 2002;21:202–210. doi: 10.1016/S0264-410X(02)00456-5. [DOI] [PubMed] [Google Scholar]
  5. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol. 1993;67:3835–3844. doi: 10.1128/jvi.67.7.3835-3844.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bocher W O, Dekel B, Schwerin W, Geissler M, Hoffmann S, Rohwer A, Arditti F, Cooper A, Bernhard H, Berrebi A, Rose-John S, Shaul Y, Galle P R, Löhr H, Reisner Y. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol. 2001;31:2071–2079. doi: 10.1002/1521-4141(200107)31:7&#x0003c;2071::AID-IMMU2071&#x0003e;3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  7. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA dependent RNA polymerase. J Antiviral Res. 2003;58(1):1–16. doi: 10.1016/S0166-3542(03)00028-7. [DOI] [PubMed] [Google Scholar]
  8. Encke J, zuPutlitz J, Geissler M, Wands J. Genetic Immunization generates cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model. J Immunol. 1998;1(61):4917–4923. [PubMed] [Google Scholar]
  9. Feltquate D M, Heaney S, Webster R G, Robinson H L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol. 1997;158:2278–2284. [PubMed] [Google Scholar]
  10. Foy E, Li K, Sumpter R, Loo Y M, Johnson C L, Wang C, Fish P M, Yoneyama M, Fujita T, Lemon S M, Gale M., Jr. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS. 2004;102(8):2986–2991. doi: 10.1073/pnas.0408707102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Frelin L, Ahlén G, Alheim M, Weiland O, Barnfield C, Liljeström P, Sällberg M. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. J Gene Ther. 2004;11(6):522–533. doi: 10.1038/sj.gt.3302184. [DOI] [PubMed] [Google Scholar]
  12. Frick D N. The hepatitis C virus NS3 protein: a model RNA helicase andpotential drug target. Curr Issues Mol Biol. 2007;9(1):1–20. [PMC free article] [PubMed] [Google Scholar]
  13. Gao M, Wang H P, Wang Y N, Zhou Y, Wang Q L. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4+ Th1 cell responses in vivo. Vaccine. 2006;24:5491–5497. doi: 10.1016/j.vaccine.2006.04.004. [DOI] [PubMed] [Google Scholar]
  14. Geissler M, Gesien A, Tokushige K, Wands J R. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine expressing plasmids. J Immunol. 1997;158:1231–1237. [PubMed] [Google Scholar]
  15. Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi M, Ebtekar E. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. J Comp immunol microbiol Infect Dis. 2007;30(4):197–210. doi: 10.1016/j.cimid.2007.01.002. [DOI] [PubMed] [Google Scholar]
  16. Ghaemi A, Soleimanjahi H, Gill P, Zuhair H, Razeghi M, Jahromi S, Roohvand F. Recombinant λ-phage nanobioparticles for tumor therapy in mice models. J Genet Vaccines Ther. 2010;8(3):1–7. doi: 10.1186/1479-0556-8-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ghaemi A, Soleimanjahi H, Gill P, Zuhair M H, Razeghi S, Fazeli M, Razavinikoo S M H. Protection of Mice by a -Based Therapeutic Vaccine against Cancer Associated with Human Papillomavirus Type 16. J Intervirol. 2009;54:105–112. doi: 10.1159/000320197. [DOI] [PubMed] [Google Scholar]
  18. Gherardi M M, Ramirez J C, Esteban M. Interleukin-12 (IL-12) Enhancement of the Cellular Immune Response against Human Immunodeficiency Virus Type 1 Env Antigen in a DNA Prime/Vaccinia Virus Boost VaccineRegimen Is Time and Dose Dependent: Suppressive Effects of IL-12 Boost Are Mediated by Nitric Oxide. J Virol. 2000;74:6278–6286. doi: 10.1128/JVI.74.14.6278-6286.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. J Annu Rev Immunol. 2002;20:621–667. doi: 10.1146/annurev.immunol.20.100301.064828. [DOI] [PubMed] [Google Scholar]
  20. Gurunathan S, Klinman D M, Seder R A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000;18:927–974. doi: 10.1146/annurev.immunol.18.1.927. [DOI] [PubMed] [Google Scholar]
  21. Ha S J, Jeon B Y, Kim S C, Kim D J, Song M K, Sung Y C, Cho S N. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with mycobacterium tuberculosis. J Gene Ther. 2003;10:1543. doi: 10.1038/sj.gt.3302042. [DOI] [PubMed] [Google Scholar]
  22. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol. 1993;67:4665–4675. doi: 10.1128/jvi.67.8.4665-4675.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Jiao X, Wang R Y, Feng Z, Hu G, Alter H J, and W-K Shih J. DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response. 2004. J Viral Hepatol, 11(1):18–26. [DOI] [PubMed]
  24. Kim J J, Ayyavoo V, Bagarazzi M L, Chattergoon M A, Dang K, Wang B, Boyer J D, Weiner D B. In vivoengineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol. 1997;158:816–826. [PubMed] [Google Scholar]
  25. Kieper W C, Tan J T, Bondi-Boyd B, Gapin L, Sprent J, Ceredig R, Surh C D. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J Exp Med. 2002;195:1533. doi: 10.1084/jem.20020067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kieper W C, Prlic M, Schmidt C S, Mescher M F, Jameson S C. Il-12 enhances CD8+ T cell homeostatic expansion. J Immunol. 2001;166:5515. doi: 10.4049/jimmunol.166.9.5515. [DOI] [PubMed] [Google Scholar]
  27. Koff R S. Hepatitis vaccines: recent advances. Int J Parasitol. 2003;33:517–523. doi: 10.1016/S0020-7519(03)00065-1. [DOI] [PubMed] [Google Scholar]
  28. Lanford R E, Guerra B, Chavez D, Bigger C, Brasky K M, Wang X H, Ray S C, Thomas D L. Cross-genotype immunity to hepatitis C virus. J Virol. 2004;78(3):1575–1581. doi: 10.1128/JVI.78.3.1575-1581.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lang K A, Yan J, Draghia-Akli R, Khan A, Weiner D B. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine. 2008;26(49):6225–6231. doi: 10.1016/j.vaccine.2008.07.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lauer G M, Walker B D. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52. doi: 10.1056/NEJM200107053450107. [DOI] [PubMed] [Google Scholar]
  31. Martin T. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther. 1999;10(5):759–768. doi: 10.1089/10430349950018517. [DOI] [PubMed] [Google Scholar]
  32. Nichols W W. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995;772:30–39. doi: 10.1111/j.1749-6632.1995.tb44729.x. [DOI] [PubMed] [Google Scholar]
  33. Semmo N, Day C L, Ward S M, Lucas M, Harcourt G, Loughry A, Klenerman P. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. J Hepatol. 2005;41(5):1019–1102. doi: 10.1002/hep.20669. [DOI] [PubMed] [Google Scholar]
  34. Pang P S, Jankowsky E, Planet P J, Pyle A M. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J. 2002;21:1168–1176. doi: 10.1093/emboj/21.5.1168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pawlotsky J M. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol. 2009;6(7):383–385. doi: 10.1038/nrgastro.2009.102. [DOI] [PubMed] [Google Scholar]
  36. Schmidt C S, Mescher M F. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD81 T cells in vivo. J Immunol. 1999;163:2561. [PubMed] [Google Scholar]
  37. Scott P, Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Semin J Immunol. 1997;9:285–291. doi: 10.1006/smim.1997.0084. [DOI] [PubMed] [Google Scholar]
  38. Sin J I, Kim J J, Arnold R L, Shroff K E, McCallus D, Pachuk C, McElhiney S P, Wolf M W, Pompa-de Bruin S J, Higgins T J, Ciccarelli R B, Weiner D B. IL-12 Gene as a DNA Vaccine Adjuvant in a Herpes Mouse Model: IL-12 Enhances Th1-Type CD4+ T Cell-Mediated Protective Immunity against Herpes Simplex Virus-2 Challenge. J Immunol. 1999;162:2912–2921. [PubMed] [Google Scholar]
  39. Shan M M, Liu K Z, Fang H L, Chen Z. DNA immune responses induced by codelivery of IL-12 expression vectors with hepatitis C structural antigen. HBPD INT. 2002;1(4):553–557. [PubMed] [Google Scholar]
  40. Tokushige K, Wakita T, Pachuk C, Moradpour D, Wener D B, Zurawski J R V R, Wands J R. Expression and Immune Response to Hepatitis C Virus Core DNA-Based Vaccine Constructs. J Hepatol. 1996;24:14–20. doi: 10.1002/hep.510240104. [DOI] [PubMed] [Google Scholar]
  41. Weck K. Molecular methods of hepatitis C genotyping. Expert Rev Mol Diagn. 2005;5(4):507–520. doi: 10.1586/14737159.5.4.507. [DOI] [PubMed] [Google Scholar]
  42. Weiner A J, Paliard X, Selby M J, Medina-Selby A, Coit D, Nguyen S, Kansopon Joe L, Arian C, Ng P, Tucker J, Lee C-T, Polakos N, Han J, Wong S, Lu H-H, Rosenberg S, Brasky K, Chien D, Kuo G, Houghton M. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol. 2001;75(15):7142–7148. doi: 10.1128/JVI.75.15.7142-7148.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Xiang Z, Ertl H C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. J Immunity. 1995;2:129–135. doi: 10.1016/S1074-7613(95)80001-8. [DOI] [PubMed] [Google Scholar]
  44. Yang S H, Lee C G, Park S H, Im S J, Kim Y M, Son J M, Wang J S, Yoon S K, Song M K, Ambrozaitis A, Kharchenko N, Yun Y D, Kim C M, Kim C Y, Lee S H, Kim B M, Kim W B, Sung Y C. Correlation of antiviral Tcell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. J Gene Ther. 2006;13(14):1110–1117. doi: 10.1038/sj.gt.3302751. [DOI] [PubMed] [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Wuhan Institute of Virology, Chinese Academy of Sciences

RESOURCES